

### Quarter End Statement of Investments

3rd Quarter as at September 30, 2022

Industry Allocation	% of Net Asset Value	Top 25 Holdings	% of Net Asset Value
Pharmaceuticals and Biotechnology	42.00%	Molina Healthcare, Inc.	2.62%
Medical Equipment and Services	29.76%	Sarepta Therapeutics, Inc.	2.62%
Health Care Providers	28.53%	Regeneron Pharmaceuticals, Inc.	2.59%
Cash & Cash Equivalents	0.37%	Cigna Corporation	2.34%
<b>Total</b>	<b>100.66%</b>	Humana Inc.	2.30%
<b>Other Assets and Liabilities</b>	<b>(0.66%)</b>	Vertex Pharmaceuticals Incorporated	2.28%
<b>Total Net Asset Value</b>	<b>100.00%</b>	UnitedHealth Group Incorporated	2.18%
		Ionis Pharmaceuticals, Inc.	2.12%
		Merck & Co., Inc.	2.10%
		Elevance Health Inc.	2.09%
		Hologic, Inc.	2.07%
		Quest Diagnostics Incorporated	2.05%
		Universal Health Services, Inc. (Class B)	1.95%
		Neurocrine Biosciences, Inc.	1.94%
		Laboratory Corporation of America Holdings	1.94%
		HCA Healthcare, Inc.	1.94%
		Signify Health, Inc. (Class A)	1.88%
		Moderna, Inc.	1.84%
		Viatis Inc.	1.81%
		Eli Lilly and Company	1.77%
		Alnylam Pharmaceuticals, Inc.	1.72%
		Premier, Inc. (Class A)	1.69%
		Exelixis, Inc.	1.67%
		Amgen Inc.	1.65%
		Biogen Inc.	1.64%
		<b>Total Net Asset Value</b>	<b>\$19,348,891</b>

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the simplified prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Data is as of September 30, 2022 (unaudited).

(10/22)